High Cholesterol and Cardiovascular Disease Research Study
This research study is evaluating an investigational drug that may help prevent major cardiac events such as heart attacks or strokes which are linked to cardiovascular disease (CVD). CVD is the leading cause of death worldwide and is associated with high levels of low-density lipoprotein cholesterol (LDL-C). Available treatments like statins have been seen to reduce the risk of cardiac events by lowering the levels of LDL-C. Despite this, lots of people require a more intensive management especially those at a higher risk of major adverse cardiovascular events hence the purpose of this research.
The study may be an option if you:
- Are aged 40 years or over.
- Have had a heart attack, stroke, or peripheral artery disease (PAD)
- Are on a stable and well-tolerated lipid-lowering regimen (including e.g., with or without Ezetimibe) that must include a high-intensity statin therapy with either atorvastatin ≥ 40mg or rosuvastatin ≥ 20mg.
- Have no history of heart failure or active liver disease.
- Other criteria apply.
Qualified participants may receive the study drug and will receive study-related evaluations and care at no cost. Reimbursement for travel and expenses may be available.
Submit to learn more:
Please note: You may or may not benefit medically from taking part and you are able to opt out at anytime and do not have to give us a reason for doing so. Your primary care physician will be informed about your participation and all medical assessments that will be carried out as part of the study. If during screening any abnormal results are found your primary care physician will also be informed.